PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
30606762-0	2019	Endothelial Cell-Targeted Deletion of PPARgamma Blocks Rosiglitazone-Induced Plasma Volume Expansion and Vascular Remodeling in Adipose Tissue.	Rosiglitazone	55-68	peroxisome proliferator activated receptor gamma	Mus musculus	38-47	
30606762-3	2019	Compared with Pparg-floxed wild-type control (Pparg f/f) mice, Pparg DeltaEC treated with rosiglitazone are resistant to an increase in extracellular fluid, water content in epididymal and inguinal white adipose tissue, and plasma volume expansion.	Rosiglitazone	90-103	peroxisome proliferator activated receptor gamma	Mus musculus	14-19	
30606762-3	2019	Compared with Pparg-floxed wild-type control (Pparg f/f) mice, Pparg DeltaEC treated with rosiglitazone are resistant to an increase in extracellular fluid, water content in epididymal and inguinal white adipose tissue, and plasma volume expansion.	Rosiglitazone	90-103	peroxisome proliferator activated receptor gamma	Mus musculus	46-51	
30606762-3	2019	Compared with Pparg-floxed wild-type control (Pparg f/f) mice, Pparg DeltaEC treated with rosiglitazone are resistant to an increase in extracellular fluid, water content in epididymal and inguinal white adipose tissue, and plasma volume expansion.	Rosiglitazone	90-103	peroxisome proliferator activated receptor gamma	Mus musculus	46-51	
30606762-4	2019	Interestingly, histologic assessment confirmed significant rosiglitazone-mediated capillary dilation within white adipose tissue of Pparg f/f mice, but not Pparg DeltaEC mice.	Rosiglitazone	59-72	peroxisome proliferator activated receptor gamma	Mus musculus	132-137	
30606762-7	2019	Together, these results indicate that rosiglitazone has direct effects on the endothelium via PPARgamma activation and point toward a critical role for PPARgamma in ECs during rosiglitazone-mediated plasma volume expansion.	Rosiglitazone	38-51	peroxisome proliferator activated receptor gamma	Mus musculus	94-103	
30606762-7	2019	Together, these results indicate that rosiglitazone has direct effects on the endothelium via PPARgamma activation and point toward a critical role for PPARgamma in ECs during rosiglitazone-mediated plasma volume expansion.	Rosiglitazone	176-189	peroxisome proliferator activated receptor gamma	Mus musculus	152-161